Circulating tumor cells (CTCs) enter peripheral blood from primary tumors and seed metastases. The genome sequencing of CTCs could offer noninvasive prognosis or even diagnosis, but has been hampered by low single-cell genome coverage of scarce CTCs. Here, we report the use of the recently developed multiple annealing and looping-based amplification cycles for whole-genome amplification of single CTCs from lung cancer patients. We observed characteristic cancer-associated single-nucleotide variations and insertions/deletions in exomes of CTCs. These mutations provided information needed for individualized therapy, such as drug resistance and phenotypic transition, but were heterogeneous from cell to cell. In contrast, every CTC from an indi...
Abstract Circulating tumor cells are tumor cells with high vitality and high metastatic potential th...
We demonstrate proof-of-concept for the use of massively multiplexed PCR and next-generation sequenc...
Background Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity ...
IntroductionCirculating tumor cells (CTCs) and cell-free tumor DNA (ctDNA) are tumor components pres...
Non-small-cell lung cancer (NSCLC) accounts for most cancer-related deaths worldwide. Liquid biopsy ...
In most patients with small-cell lung cancer (SCLC)—a metastatic, aggressive disease—the condition i...
Simple Summary Circulating tumor cells (CTCs) are rare cells found in the bloodstream of oncologic p...
Abstract Background Solid tumors residing in tissues and organs leave footprints in circulation thro...
Cancer is a disease of complex genetic alterations, and comprehensive genetic diagnosis is beneficia...
Circulating tumor cells (CTCs) are a rare population of cells representing a key player in the metas...
Abstract Gatekeeper mutations are identified in only 50% of the cases at resistance to Anaplastic Ly...
Several studies have shown heterogeneity in lung cancer, with parallel existence of multiple subclon...
Previous studies have demonstrated focal but limited molecular similarities between circulating tumo...
Non-small-cell lung cancer (NSCLC) accounts for most cancer-related deaths worldwide. Liquid biopsy ...
Genomic instability is a hallmark of cancer often associated with poor patient outcome and resistanc...
Abstract Circulating tumor cells are tumor cells with high vitality and high metastatic potential th...
We demonstrate proof-of-concept for the use of massively multiplexed PCR and next-generation sequenc...
Background Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity ...
IntroductionCirculating tumor cells (CTCs) and cell-free tumor DNA (ctDNA) are tumor components pres...
Non-small-cell lung cancer (NSCLC) accounts for most cancer-related deaths worldwide. Liquid biopsy ...
In most patients with small-cell lung cancer (SCLC)—a metastatic, aggressive disease—the condition i...
Simple Summary Circulating tumor cells (CTCs) are rare cells found in the bloodstream of oncologic p...
Abstract Background Solid tumors residing in tissues and organs leave footprints in circulation thro...
Cancer is a disease of complex genetic alterations, and comprehensive genetic diagnosis is beneficia...
Circulating tumor cells (CTCs) are a rare population of cells representing a key player in the metas...
Abstract Gatekeeper mutations are identified in only 50% of the cases at resistance to Anaplastic Ly...
Several studies have shown heterogeneity in lung cancer, with parallel existence of multiple subclon...
Previous studies have demonstrated focal but limited molecular similarities between circulating tumo...
Non-small-cell lung cancer (NSCLC) accounts for most cancer-related deaths worldwide. Liquid biopsy ...
Genomic instability is a hallmark of cancer often associated with poor patient outcome and resistanc...
Abstract Circulating tumor cells are tumor cells with high vitality and high metastatic potential th...
We demonstrate proof-of-concept for the use of massively multiplexed PCR and next-generation sequenc...
Background Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity ...